Department of Dermatology and Venereology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria.
Wien Klin Wochenschr. 2024 Nov;136(21-22):590-597. doi: 10.1007/s00508-024-02435-0. Epub 2024 Sep 11.
Vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) was one crucial element to overcome the coronavirus disease 2019 (COVID-19) pandemic. Even though anaphylaxis to vaccines is rare, 47 patients came to the Allergy Unit at the University Hospital Graz, Austria, reporting immediate anaphylactoid symptoms after administration of COVID-19 vaccines. In addition, 29 patients with known drug-induced anaphylaxis wanted to be tested for a possible sensitization against COVID-19 vaccines or excipients, such as polyethylene glycol (PEG) or polysorbate 80 (PS80) before the first COVID-19 vaccination. Skin prick tests and intradermal tests were performed in all 76 patients, mostly using PEG 2000, and/or PS80. Skin prick tests with COVID-19 vaccines were performed depending on availability.
Our aim was to characterize this patient cohort in terms of patients' anaphylactoid responses, their willingness to future vaccinations against SARS-Cov‑2, and reasons for their decision.
We developed a questionnaire and analyzed 34 completed copies.
Of the 47 patients with anaphylactoid reactions to COVID-19 vaccination, most were female (40 female/7 male). The skin tests, even when performed with the respective COVID-19 vaccine, were negative in all but one patient. Most patients who experienced anaphylactoid reactions after a COVID-19 vaccination, did not want another COVID-19 vaccination at the time of answering the questionnaire because of anxiety for another anaphylactoid response at the next shot. Premedication with antihistamines significantly lowered (n = 74 vaccinations) the severity of anaphylactoid responses after COVID-19 vaccinations.
Anxiety about another anaphylactoid episode hinders patients to be vaccinated against SARS-CoV‑2 again. Premedication with antihistamines and collaboration of allergologists with psychologists might lower the risk of an anaphylactic/anaphylactoid response as well anxiety in drug-induced anaphylactic patients.
接种严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)疫苗是克服 2019 年冠状病毒病(COVID-19)大流行的关键因素之一。尽管疫苗过敏反应很少见,但奥地利格拉茨大学医院的过敏科仍有 47 名患者报告称,在接种 COVID-19 疫苗后出现即刻过敏样症状。此外,29 名已知有药物诱导过敏反应的患者希望在首次接种 COVID-19 疫苗之前,对 COVID-19 疫苗或赋形剂(如聚乙二醇(PEG)或聚山梨醇酯 80(PS80))进行可能的致敏检测。在 76 名患者中,主要使用 PEG 2000 和/或 PS80,进行了皮肤点刺试验和皮内试验。根据疫苗供应情况,进行了 COVID-19 疫苗的皮肤点刺试验。
我们旨在根据患者的过敏样反应、他们对未来 SARS-CoV-2 疫苗接种的意愿以及他们做出决定的原因,对这一患者群体进行特征描述。
我们设计了一份问卷并对 34 份已完成的问卷进行了分析。
在 47 名对 COVID-19 疫苗接种出现过敏样反应的患者中,大多数为女性(40 名女性/7 名男性)。除了 1 名患者外,所有患者的皮肤试验,即使是用相应的 COVID-19 疫苗进行的,结果均为阴性。大多数在接种 COVID-19 疫苗后出现过敏样反应的患者,在回答问卷时因担心下一次接种会出现过敏样反应,不想再接种 COVID-19 疫苗。在 COVID-19 疫苗接种前使用抗组胺药进行预处理(n=74 次接种)显著降低了过敏样反应的严重程度。
对再次发生过敏样反应的焦虑阻碍了患者接种 SARS-CoV-2 疫苗。在药物诱导过敏反应患者中,使用抗组胺药进行预处理以及过敏科医生与心理学家合作,可能会降低发生过敏/过敏样反应以及焦虑的风险。